International Clinical Trial: Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07738172) titled 'Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer' on July 23.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: National Taiwan University Hospital

Condition: Lung Neoplasms, Non-Small Cell Lung Cancer

Intervention: Procedure: Primary Tumor Resection

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: August 1, 2026

Target Sample Size: 154

Countries of Recruitment: Taiwan

To know more, ...